8.54
-0.64 (-6.97%)
8.63
+0.09 (+1.05%)
ChartMill assigns a Buy % Consensus number of 100% to CATB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 24.23. This target is 183.67% above the current price.
CATB was analyzed by 4 analysts. The buy percentage consensus is at 100. So analysts seem to be very confident about CATB.
In the last month the buy percentage rose by 13 points. So the trust of analysts is improving.
Only 4 analysts analyzed CATB. So this is just the average opinion of a couple of analysts.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-09-02 | Wedbush | Initiate | Outperform |
| 2021-08-25 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2021-05-12 | Ladenburg Thalmann | Initiate | Buy |
| 2021-03-11 | Oppenheimer | Upgrade | Perform -> Outperform |
Catabasis Pharma / CATB FAQ
Can you provide the average price target for Catabasis Pharma stock?
4 analysts have analysed CATB and the average price target is 24.23 null. This implies a price increase of 183.67% is expected in the next year compared to the current price of 8.54.
What is the consensus rating for CATB stock?
The consensus rating for Catabasis Pharma (CATB) is 100 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for CATB stock?
The number of analysts covering Catabasis Pharma (CATB) is 4.